A phase 2a randomized study to evaluate the safety and immunogenicity of the 1790GAHB GMMA vaccine against Shigella sonnei administered intramuscularly to adults from a shigellosis-endemic country

A phase 2a randomized study to evaluate the safety and immunogenicity of the 1790GAHB GMMA vaccine against Shigella sonnei administered intramuscularly to adults from a shigellosis-endemic country

Shigellosis is a mild-to-severe diarrheal infection caused by the genus Shigella and responsible for significant morbidity and mortality worldwide. We evaluated the safety and immunogenicity of an investigational Shigella sonnei vaccine (1790GAHB) based on Generalized Modules for Membrane Antigens (...

Full description

Bibliographic Details
Main Authors: Obiero, C, Ndiaye, A, Scirè, A, Kaunyangi, B, Marchetti, E, Gone, A, Schütte, L, Riccucci, D, Auerbach, J, Saul, A, Martin, L, Bejon, P, Njuguna, P, Podda, A
Format: Journal article
Published: Frontiers Media 2017

Similar Items

Similar Items